At Sinnovision, we use advanced genomics to enhance precision medicine in cancer care. Our hereditary cancer tests analyze 79 genes linked to various cancers, including breast, ovarian, colorectal, pancreatic, prostate, and stomach cancers. These tests detect genetic alterations such as SNVs, Indels, and CNVs, providing crucial insights for early detection and treatment.

We offer specialized tests for specific cancers, like our non-invasive lung cancer test, which covers genes with therapeutic implications for targeted drugs. Utilizing next-generation sequencing, these tests detect a wide range of genomic alterations from both tissue samples and liquid biopsies.

We can identify actionable genomic alterations across 688 cancer-related genes, supporting detailed mutation analysis and pharmacogenomics. These advanced diagnostics enable us to deliver precise, personalized cancer care, improving patient outcomes through targeted treatment strategies.